Cargando…
Extent of Surgery Does Not Influence 30-Day Mortality in Surgery for Metastatic Bone Disease: An Observational Study of a Historical Cohort
Estimating patient survival has hitherto been the main focus when treating metastatic bone disease (MBD) in the appendicular skeleton. This has been done in an attempt to allocate the patient to a surgical procedure that outlives them. No questions have been addressed as to whether the extent of the...
Autores principales: | Sørensen, Michala Skovlund, Hindsø, Klaus, Hovgaard, Thea Bechmann, Petersen, Michael Mørk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839836/ https://www.ncbi.nlm.nih.gov/pubmed/27082592 http://dx.doi.org/10.1097/MD.0000000000003354 |
Ejemplares similares
-
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021) -
Dislocation rate after hip arthroplasty due to metastatic bone disease: a retrospective cohort study evaluating the postoperative dislocation risk across different articulating solutions
por: ILJAZI, Afrim, et al.
Publicado: (2023) -
Use of endoprostheses for proximal femur metastases results in a rapid rehabilitation and low risk of implant failure. A prospective population-based study
por: Sørensen, Michala Skovlund, et al.
Publicado: (2019) -
Major surgery for metastatic bone disease is not a risk for 30-day mortality: a population-based study from Denmark
por: LADEGAARD, Thea H, et al.
Publicado: (2023) -
Surgical Treatment of Metastatic Bone Disease—When Decisions at End-of-Life Really Makes the Difference
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)